Retatrutide, a new dual agonist of the GLP-1 binding site and glucose-dependent released polypeptide (GIP) binding site , is exhibiting promising results in initial patient trials . Current inquiry https://thefairlist.com/story11591094/retatrutide-emerging-studies-and-projected-clinical-applications